Core Viewpoint - The article discusses the complex interactions between cancer cells and the tumor microenvironment (TME), emphasizing the potential of targeted cancer immunotherapies to disrupt immunosuppressive interactions, although many therapies show limited durability due to a lack of understanding of these interactions [2][3]. Group 1: Research Findings - A study published by a team from the University of Chicago reveals that tumor-initiating stem cells (tSC) regulate the plasticity of neutrophils through metabolic reprogramming, creating a protective niche that allows them to survive cancer immunotherapy, leading to cancer recurrence [4]. - The research indicates that targeting the SOX2-FADS1-PGE2 signaling axis could serve as a novel combination therapy strategy to prevent immunotherapy resistance and tumor recurrence [4]. Group 2: Mechanisms of Immune Evasion - The study highlights the heterogeneity of tumor-associated neutrophils (TAN) and how different states of TAN arise and evolve, impacting the effectiveness of cancer immunotherapy [8]. - It was found that anti-PDL1 + CD40 agonist immunotherapy can induce TAN to regain anti-tumor activity in squamous cell carcinoma (SCC), while TAN at the tumor-stroma interface maintain their immunosuppressive state [8]. Group 3: Key Pathways and Implications - The SOX2 high-expressing tSCs enhance PGE2 signaling in TAN, which may disrupt interferon responses and inhibit the anti-tumor functions of TAN [9]. - Specific knockout of PGE2 receptors in neutrophils or using COX-2 inhibitors to block PGE2 synthesis can effectively restore the anti-tumor functions of neutrophils, enhancing the efficacy of immunotherapy and significantly reducing tumor recurrence rates [9]. Group 4: Overall Conclusions - The research explores how effective immunotherapies influence the plasticity of TAN, revealing how tSCs evade TAN-mediated anti-tumor immunity, allowing them to survive cancer immunotherapy and promote recurrence [12].

Core Viewpoint - Cancer immunotherapy has transformed cancer treatment, but many patients do not respond. Activating innate immunity presents a promising method to enhance treatment efficacy, yet the specific signal kinases involved remain largely unknown [3]. Group 1: Research Findings - A recent study published in Nature Cancer identified CDK10 as a key driver of immune evasion in cancer cells, which suppresses antitumor immunity by limiting the production of immunostimulatory nucleic acids [3][4]. - The research utilized in vivo CRISPR screening to establish CDK10 as a critical inhibitory factor in tumor immune surveillance [4]. - CDK10 reduces the accumulation of double-stranded RNA and R-loops by phosphorylating DNMT1 and RAP80, thereby dampening the activation of innate immune pathways mediated by MDA5 and cGAS [4]. Group 2: Clinical Implications - The study confirmed that lower expression levels of CDK10 in tumors correlate with better responses to immunotherapy in cancer patients [5]. - These findings position CDK10 as a significant regulatory factor in tumor immunity and a potential therapeutic target [6]. Group 3: Related Commentary - A commentary published alongside the study in Nature Cancer highlighted that the activation of cytoplasmic nucleic acid sensors in tumor cells is a crucial early step in initiating antitumor immunity, although the mechanisms controlling their activity are not fully understood [6].

Core Viewpoint - The article discusses the significant clinical challenge of peritoneal metastasis in solid tumors and highlights the potential of CAR macrophage (CAR-M) therapy as a promising immunotherapy approach to address this unmet clinical need [2][7]. Group 1: Clinical Challenges and Current Treatments - Peritoneal metastasis from solid tumors poses a major clinical challenge, with current treatments like cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) only benefiting a small subset of patients with very low tumor burden [2]. - Immunotherapy is seen as a promising frontier for treating peritoneal metastasis, but many patients develop escape mechanisms against the immune system, leading to disease progression and poor prognosis [2]. Group 2: CAR-M Therapy Development - The research led by Chinese Academy of Sciences explores 36 different CAR combinations targeting macrophages, utilizing an mRNA lipid nanoparticle (LNP) system for efficient in vivo construction of CAR-M cells necessary for tumor immunotherapy [3][7]. - The study demonstrates that intraperitoneal programming of CAR-M cells can induce robust adaptive immune system activation and significantly enhance the efficacy of standard PD-1/PD-L1 immune checkpoint blockade therapies in resistant models [4][7]. Group 3: Mechanisms and Findings - Customized CAR-M cells with CD3ζ and TLR4 transmembrane domains can trigger strong adaptive immune activation and significantly synergize with PD-1/PD-L1 therapies [7]. - Single-cell RNA sequencing (scRNA-seq) reveals that CAR-M cells reshape the immunosuppressive tumor microenvironment (TME) and promote the formation of TCF1+ PD-1+ exhausted CD8+ T cell populations [4][7]. - Mechanistically, CAR-M cells maintain a pro-inflammatory phenotype while upregulating MHC-I and PD-L1 through interference with the NF-κB pathway [4][7]. Group 4: Conclusion and Future Directions - The study develops an mRNA-LNP delivery system for targeted in vivo programming of CAR-M cells, deepening the understanding of the regulatory and feedback mechanisms of CAR-M therapy in treating solid tumors [10].

Core Viewpoint - The study identifies two opposing subsets of regulatory T cells (Treg cells) in colorectal cancer: IL-10⁺ Treg cells, which are anti-tumor, and IL-10⁻ Treg cells, which are pro-tumor, suggesting a potential for targeted cancer immunotherapy by preserving anti-tumor Treg cells while selectively depleting pro-tumor Treg cells [3][7][11]. Group 1 - The research highlights the heterogeneity of tumor-associated Treg cells in colorectal cancer, identifying IL-10⁺ Treg cells and IL-10⁻ Treg cells as distinct subsets with opposing functions [5][10]. - Selective depletion of IL-10⁺ Treg cells promotes tumor growth by removing their inhibitory effect on effector CD4⁺ T cells, while depleting IL-10⁻ Treg cells leads to significant tumor regression [5][10]. - The abundance of IL-10⁺ Treg cells correlates with good prognosis, whereas IL-10⁻ Treg cells are associated with poor prognosis in human colorectal cancer [6][11]. Group 2 - The study suggests that the functional dichotomy of Treg cell subsets may be a universal phenomenon observed in other barrier tissues such as skin, lungs, and gastrointestinal tract tumors [3][7]. - This research proposes a new paradigm for cancer immunotherapy, shifting from a broad approach of enhancing or suppressing the entire immune system to a more precise strategy of targeting immunosuppressive Treg cell subsets while preserving protective ones [11].

Core Viewpoint - The company, Junshi Biosciences (复宏汉霖), announced that its self-developed innovative anti-PD-1 monoclonal antibody, Hansizhuang® (Sruvilizumab), has received acceptance for its New Drug Application (NDA) from the National Medical Products Administration (NMPA) for use in neoadjuvant therapy combined with platinum-based chemotherapy for PD-L1 positive, resectable gastric cancer patients, and has been included in the priority review process [1] Group 1 - The acceptance of the NDA and inclusion in the priority review process will significantly shorten the review timeline to 130 working days, accelerating the market entry process for Hansizhuang in the perioperative treatment of gastric cancer [1] - Hansizhuang is expected to become the world's first approved anti-PD-1 monoclonal antibody for this indication, marking a significant milestone in the treatment of gastric cancer [1] - The CEO of Junshi Biosciences, Dr. Jun Zhu, stated that this acceptance signifies the formal entry of Hansizhuang into the "fast track" for market approval, highlighting the potential for improved patient quality of life and survival benefits [1] Group 2 - Previously, Hansizhuang was included in the breakthrough therapy designation list by the Center for Drug Evaluation (CDE), being the first drug recognized in the perioperative treatment field for gastric cancer [1] - The CDE agreed to include Hansizhuang in the priority review process due to its alignment with the criteria for expedited evaluation [1]

Core Viewpoint - A research team from Zhejiang University has developed a novel cancer immunotherapy platform by repurposing mast cells, traditionally involved in allergic reactions, to deliver anti-cancer drugs directly to tumor sites, enhancing the immune response against cancer [2][5]. Group 1: Research Background and Methodology - The study published in the journal Cell describes a targeted therapy platform using engineered mast cells that act as "couriers" to deliver anti-tumor drugs by utilizing tumor-associated antigens as "allergens" [2][5]. - The engineered mast cells, sensitized with IgE antibodies specific to tumor markers, can migrate to tumor sites and trigger a rapid immune response, transforming "cold tumors" into "hot tumors" that are more susceptible to immune attack [5][11]. Group 2: Drug Delivery Mechanism - The engineered IgE-MC platform can carry various therapeutic agents, including oncolytic viruses, chemotherapy drugs, immune checkpoint inhibitors, and mRNA vaccines, with a focus on delivering oncolytic viruses [7][9]. - The oncolytic viruses can selectively infect and lyse tumor cells, and the IgE-MC protects these viruses from being cleared by the immune system during intravenous administration [9][10]. Group 3: Efficacy and Safety - In mouse models, treatment with OV@IgE-MC showed significant efficacy, with 60% of mice surviving beyond 25 days in the B16F10-OVA melanoma model, compared to a control group that all died within 15 days [11][12]. - Safety assessments indicated that injected IgE-MC are cleared within two weeks without disrupting mast cell homeostasis or inducing systemic allergic reactions, and they reduced liver toxicity compared to free oncolytic viruses [16][15]. Group 4: Future Prospects - The technology allows for personalized cancer treatment by matching specific IgE antibodies to patient tumor markers, simplifying the preparation process compared to traditional CAR-T cell therapies [18][19]. - The research team plans to establish a screening process for patient-specific IgE and explore combinations with existing immunotherapies, aiming to bring this innovative "tumor allergy" therapy from the lab to clinical application [19][18].

Core Viewpoint - Cancer immunotherapy has revolutionized cancer treatment by activating the immune system to attack tumors, but many patients still face tumor recurrence, with underlying mechanisms not fully understood [1][4]. Group 1: Tumor-Initiating Stem Cells (tSC) - Tumor-initiating stem cells (tSC) are considered a key cell population responsible for tumor recurrence, yet their role in regulating the immune microenvironment remains largely unknown [1][5]. - Recent research indicates that tSC can survive during strong anti-tumor immune responses induced by immunotherapy, contributing to cancer recurrence post-treatment [5][10]. Group 2: Neutrophils in Tumor Microenvironment - Neutrophils, as one of the most abundant immune cells in the tumor microenvironment (TME), have a close relationship with the effectiveness of immunotherapy [1][4]. - Tumor-associated neutrophils (TAN) have been traditionally viewed as having immunosuppressive roles, but recent studies suggest they can enhance anti-tumor immune responses by presenting new antigens through MHCII molecules [1][6]. Group 3: Research Findings - A study published in Cancer Cell reveals that tSC regulate the plasticity of neutrophils through metabolic reprogramming, creating a protective niche that allows them to survive during cancer immunotherapy, leading to recurrence [2][10]. - The study identifies a specific signaling axis (SOX2-FADS1-PGE2) that could serve as a novel combination therapy strategy to prevent immunotherapy resistance and tumor recurrence [2][10]. Group 4: Implications of Findings - The research highlights the dynamic interactions between tSC and TAN, showing that effective immunotherapy can induce different responses in various TAN subpopulations [8][10]. - The findings suggest that targeting the PGE2 signaling pathway can restore the anti-tumor functions of neutrophils, enhancing the effectiveness of immunotherapy and significantly reducing tumor recurrence rates [7][12].

撰文丨王聪 编辑丨王多鱼 排版丨水成文 肝细胞癌 （HCC） 是 肝癌 的主要亚型，也是全球癌症相关死亡的主要原因之一，其发病率和死亡率一直 居高不下。 肿瘤相关巨噬细胞 （TAM） 在塑造 肝细胞癌 （HCC） 的免疫微环境中发挥着着关键作用， 影响肿瘤进展和免疫治疗反应。 N 7 -甲基鸟苷 （m 7 G） 是一 种常见的 RNA 表观遗传修饰， WDR4 是 m 7 G 甲基转 移酶复合物中的一 种 tRNA 结合辅助因子，但其独立功能仍知之甚少。 在这项最新研究中，研究团队发现， WDR4 在 肝细胞癌 （HCC） 相关的 肿瘤相关巨噬细胞 （TAM） 中 的表达显著上调，并与不良预后相关。 单核细胞来源的巨噬细胞中 WDR4 的缺失 （而不是驻留 Kupffer 细胞 中的 WDR4 缺失） ， 会将肿瘤相关巨噬细胞 （TAM） 编程为抗肿瘤表型，从而抑制肝细胞癌 （HCC） 的进展。 从机制上来说，细胞质中的 WDR4 通过直接与 eIF4E2 相互作用，独立于 m 7 G 修饰来增强 eIF4E 介导 的 ABCA1 的选择性翻译，从而促进膜胆固醇外流并维持促肿瘤极化。利用 CpG-siRNA ...

Core Viewpoint - The article discusses the dual role of ADAR1 protein in maintaining immune balance and its involvement in cancer progression, highlighting the potential for developing ADAR1 inhibitors for cancer treatment [3][12]. Group 1: ADAR1 Functionality - ADAR1 is an RNA editing enzyme that converts adenosine (A) to inosine (I) in double-stranded RNA (dsRNA), which is recognized as guanosine (G), thus facilitating RNA-level gene editing [5]. - There are two isoforms of ADAR1: ADAR1p110, which is involved in basic RNA editing and cellular homeostasis, and ADAR1p150, which is induced by interferons and plays a critical role in suppressing excessive immune activation [5]. Group 2: ADAR1 Deficiency and Autoimmunity - Deficiency or mutation of ADAR1, particularly the p150 isoform, can lead to severe autoimmune diseases due to the exposure of unedited endogenous dsRNA, activating various cellular sensors [8][11]. - The sensors activated include MDA5, which triggers interferon expression, and PKR, which halts global protein synthesis, potentially leading to cell death [8][9]. Group 3: ADAR1 in Cancer - ADAR1 can be exploited by cancer cells to evade immune detection by upregulating its expression, thus disguising themselves from the immune system [12]. - Inhibiting ADAR1 could expose cancer cells to immune recognition, simulating a viral infection state and activating immune responses against tumors [12]. Group 4: Development of ADAR1 Inhibitors - The article outlines six strategies for developing ADAR1 inhibitors, including accumulating dsRNA, inhibiting ADAR1's binding to dsRNA, and depleting ADAR1 through targeted degradation [15][16]. - These strategies aim to enhance the immune system's ability to recognize and attack cancer cells by increasing the levels of unedited dsRNA [16]. Group 5: Future Directions - Ongoing research aims to clarify which specific endogenous dsRNAs are most likely to trigger autoimmune responses and to develop selective inhibitors targeting the ADAR1p150 isoform in cancer cells [19][25].

Core Viewpoint - The study reveals the critical role of the transcription factor IRF8 in the differentiation and function of exhausted CD8⁺ T cells in cancer, highlighting its potential as a target for new immunotherapy strategies [2][3][8]. Group 1: Research Findings - The research constructed a chromatin spatial structure map of tumor-specific exhausted CD8⁺ T cells, showing that IRF8 recruits the structural protein CTCF to reshape chromatin architecture and regulate gene expression, thereby influencing the differentiation and anti-tumor functions of exhausted CD8⁺ T cells [3][6]. - During the differentiation of CD8⁺ T cells, extensive chromatin spatial structure remodeling occurs, with 45% of structures in chromatin loops being reorganized as precursor exhausted CD8⁺ T cells (Tpex) transition to terminally differentiated exhausted CD8⁺ T cells (Ttex) [6]. - The absence of IRF8 significantly impairs the differentiation of exhausted CD8⁺ T cells and their anti-tumor functions, indicating its essential role in the spatial proximity reorganization between enhancers and promoters of genes related to T cell exhaustion [6][8]. Group 2: Implications for Immunotherapy - The findings suggest that IRF8-dependent chromatin topology plays a crucial role in the differentiation of exhausted CD8⁺ T cells, providing a potential target for developing new cancer immunotherapy strategies aimed at enhancing CD8⁺ T cell activity and improving anti-tumor immune responses [8].